Should You Buy Galecto Inc (GLTO) Stock on Monday?

The market has been high on Galecto Inc (GLTO) stock recently. GLTO gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Galecto Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on GLTO!

See Full GLTO Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With GLTO Stock Today?

Galecto Inc (GLTO) stock has gained 9.15% while the S&P 500 is down -0.04% as of 1:01 PM on Monday, Mar 4. GLTO has risen $0.07 from the previous closing price of $0.82 on volume of 476,771 shares. Over the past year the S&P 500 has risen 26.85% while GLTO is down -56.10%. GLTO lost -$1.76 per share in the over the last 12 months. To screen for more stocks like Galecto Inc click here.

More About Galecto Inc

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. Click Here to get the full Stock Report for Galecto Inc stock.